Abstract
Introduction: Preclinical data showed that intercalated administration of epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) and chemotherapy might be effective in the treatment of advanced non-small-cell lung cancer (NSCLC). This review will summarize and discuss the clinical results available to date from prospective studies investigating this approach. Areas covered: A structured search of bibliographic databases for peer-reviewed literature and of main International meetings was undertaken, for trials testing the intercalated addition of EGFR-TKIs to chemotherapy in advanced NSCLC. Expert commentary: The results of intercalated schedules of EGFR-TKI and chemotherapy are interesting but somewhat contrasting. This approach could represent a potential treatment option in patients with advanced NSCLC, that deserves to be further investigated within well-designed randomized trials.
| Original language | English |
|---|---|
| Pages (from-to) | 171-180 |
| Number of pages | 10 |
| Journal | Expert Review of Respiratory Medicine |
| Volume | 11 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - Mar 4 2017 |
Fingerprint
Keywords
- Afatinib
- chemotherapy
- EGFR
- erlotinib
- gefitinib
- icotinib
- metastatic
- mutations
- NSCLC
- tyrosine kinase inhibitor
ASJC Scopus subject areas
- Immunology and Allergy
- Pulmonary and Respiratory Medicine
- Public Health, Environmental and Occupational Health
Cite this
Chemotherapy and intercalated gefitinib or erlotinib in the treatment of advanced non-small-cell lung cancer. / Rossi, Antonio; La Salvia, Anna; Di Maio, Massimo.
In: Expert Review of Respiratory Medicine, Vol. 11, No. 3, 04.03.2017, p. 171-180.Research output: Contribution to journal › Review article
}
TY - JOUR
T1 - Chemotherapy and intercalated gefitinib or erlotinib in the treatment of advanced non-small-cell lung cancer
AU - Rossi, Antonio
AU - La Salvia, Anna
AU - Di Maio, Massimo
PY - 2017/3/4
Y1 - 2017/3/4
N2 - Introduction: Preclinical data showed that intercalated administration of epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) and chemotherapy might be effective in the treatment of advanced non-small-cell lung cancer (NSCLC). This review will summarize and discuss the clinical results available to date from prospective studies investigating this approach. Areas covered: A structured search of bibliographic databases for peer-reviewed literature and of main International meetings was undertaken, for trials testing the intercalated addition of EGFR-TKIs to chemotherapy in advanced NSCLC. Expert commentary: The results of intercalated schedules of EGFR-TKI and chemotherapy are interesting but somewhat contrasting. This approach could represent a potential treatment option in patients with advanced NSCLC, that deserves to be further investigated within well-designed randomized trials.
AB - Introduction: Preclinical data showed that intercalated administration of epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) and chemotherapy might be effective in the treatment of advanced non-small-cell lung cancer (NSCLC). This review will summarize and discuss the clinical results available to date from prospective studies investigating this approach. Areas covered: A structured search of bibliographic databases for peer-reviewed literature and of main International meetings was undertaken, for trials testing the intercalated addition of EGFR-TKIs to chemotherapy in advanced NSCLC. Expert commentary: The results of intercalated schedules of EGFR-TKI and chemotherapy are interesting but somewhat contrasting. This approach could represent a potential treatment option in patients with advanced NSCLC, that deserves to be further investigated within well-designed randomized trials.
KW - Afatinib
KW - chemotherapy
KW - EGFR
KW - erlotinib
KW - gefitinib
KW - icotinib
KW - metastatic
KW - mutations
KW - NSCLC
KW - tyrosine kinase inhibitor
UR - http://www.scopus.com/inward/record.url?scp=85013773621&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85013773621&partnerID=8YFLogxK
U2 - 10.1080/17476348.2017.1290526
DO - 10.1080/17476348.2017.1290526
M3 - Review article
VL - 11
SP - 171
EP - 180
JO - Expert Review of Respiratory Medicine
JF - Expert Review of Respiratory Medicine
SN - 1747-6348
IS - 3
ER -